Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Clinical trial NCT06660355 · RECRUITING

Trial details

NCT number: NCT06660355
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Graft-versus-host Disease (cGVHD)

Start date: 2024-12-23
Primary completion: 2028-12-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.